Giant Prolactinoma Causing Hydrocephalus and Intracranial Hypertension as First Manifestations of Multiple Endocrine Neoplasia Type 1

scientific article published on 28 August 2019

Giant Prolactinoma Causing Hydrocephalus and Intracranial Hypertension as First Manifestations of Multiple Endocrine Neoplasia Type 1 is …
instance of (P31):
scholarly articleQ13442814
case reportQ2782326

External links are
P356DOI10.3389/FENDO.2019.00582
P932PMC publication ID6722186
P698PubMed publication ID31555208

P2093author name stringDelmar M Lourenço
Manoel R A Martins
Ana R P Quidute
Carlos E L Soares
Naiara C B Dantas
P2860cites workMultiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the geneQ28249576
Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter studyQ30672269
Giant prolactinomas: clinical management and long-term follow up.Q30714659
Prolactinoma manifesting with symptomatic hydrocephalusQ33630454
Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1).Q34283436
The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes.Q34630270
An Intronic mutation is associated with prolactinoma in a young boy, decreased penetrance in his large family, and variable effects on MEN1 mRNA and proteinQ35072652
Neurological, psychiatric, ophthalmological, and endocrine complications in giant male prolactinomas: An observational study in Algerian populationQ35197949
Obstructive hydrocephalus, fifth nerve and hypothalamus involvement: acute presentation of a giant prolactinomaQ36129666
MEN1 in children and adolescents: Data from patients of a regional referral center for hereditary endocrine tumorsQ36377417
Advances in the treatment of prolactinomasQ36480692
Clinical presentation and response to therapy in patients with massive prolactin hypersecretionQ36739645
Giant prolactinoma and effectiveness of medical managementQ37585823
Long-Term Natural Course of Pituitary Tumors in Patients With MEN1: Results From the DutchMEN1 Study Group (DMSG).Q53446846
Germline mutation landscape of multiple endocrine neoplasia type 1 using full gene next-generation sequencingQ57492319
Giant Prolactinoma in Men: Clinical Features and Therapeutic OutcomesQ58554244
Giant Prolactinoma of Young Onset: A Clue to Diagnosis of MEN-1 SyndromeQ58780637
Mutation analysis of the MEN1 gene in multiple endocrine neoplasia type 1, familial acromegaly and familial isolated hyperparathyroidismQ58862086
[Haemorrhagic necrosis of a pituitary adenoma in a case of multiple endocrine neoplasia (author's transl)]Q72531509
Prolactinomas in children and adolescents. Clinical presentation and long-term follow-upQ77114106
Fluctuating confusional state due to massive macro-prolactinoma resulting in obstructive hydrocephalusQ77174067
Novel MEN1 germline mutations in Brazilian families with multiple endocrine neoplasia type 1Q80445192
The impact of clinical and genetic screenings on the management of the multiple endocrine neoplasia type 1Q81153715
Multiple endocrine neoplasia type 1 in Brazil: MEN1 founding mutation, clinical features, and bone mineral density profileQ81398600
MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d'étude des Tumeurs EndocrinesQ86546147
Pituitary adenomas in childhood, adolescence and young adulthood: presentation, management, endocrine and metabolic outcomesQ37777905
Giant prolactinomas: the therapeutic approach.Q38105620
Giant prolactinomas in womenQ38148633
Therapy of endocrine disease: the challenges in managing giant prolactinomasQ38188916
Assessment of Depression, Anxiety, Quality of Life, and Coping in Long-Standing Multiple Endocrine Neoplasia Type 2 Patients.Q38918491
Genetics of multiple endocrine neoplasia type 1 syndrome: what's new and what's old.Q39129029
Combined treatment of invasive giant prolactinomas.Q39356670
Proptosis as the presenting sign of giant prolactinoma in a prepubertal boy: successful resolution of hydrocephalus by use of medical therapyQ39504987
Treatment-resistant pediatric giant prolactinoma and multiple endocrine neoplasia type 1.Q40730569
Prolactinomas in children under 14. Clinical presentation and long-term follow-upQ41221512
Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patientsQ41659209
Treatment of extensively invasive (giant) prolactinomas with bromocriptineQ41972064
Obstructive hydrocephalus and intracranial hypertension caused by a giant macroprolactinoma. Prompt response to medical treatmentQ42484918
Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patientsQ44301609
Pituitary adenomas in adolescent patients with multiple endocrine neoplasia type 1.Q44354633
Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don't forget MEN1 genetic analysis.Q44476584
Falsely low serum prolactin in two cases of invasive macroprolactinomaQ44617301
Resolution of macroprolactinoma-induced symptomatic hydrocephalus following cabergoline therapyQ44890954
Clinical profile and long term follow up of children and adolescents with prolactinomasQ46301128
Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men.Q46869117
Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up.Q46969695
Rapid size reduction of giant prolactinoma following medical treatmentQ47242909
Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas.Q47306652
Pediatric prolactinoma: initial presentation, treatment, and long-term prognosisQ47425359
Clinical presentation and outcome of pituitary adenomas in teenagers.Q48029885
Giant invasive prolactinomasQ48186258
Surgical indication after bromocriptine therapy on giant prolactinomas: effects and limitations of the medical treatmentQ48309678
Results of treatment of pituitary disease in multiple endocrine neoplasia, type I.Q48953134
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P921main subjectintracranial hypertensionQ18558125
prolactinomaQ954831
multiple endocrine neoplasiaQ1553018
multiple endocrine neoplasia type 1Q3347154
P304page(s)582
P577publication date2019-08-28
P1433published inFrontiers in EndocrinologyQ27723680
P1476titleGiant Prolactinoma Causing Hydrocephalus and Intracranial Hypertension as First Manifestations of Multiple Endocrine Neoplasia Type 1
P478volume10